Millions Logo
home>US Stocks>Eli Lilly
LLY
Eli LillyHealthcare
$1,443.72+$425.93 (+41.85%)in 1 year
As on 14 Nov 2026 at 02:29NYSE
52 Week Low: $850.5152 Week High: $1,460.00

Eli Lilly Share Price Today

Eli Lilly opened higher at $1,429.91, compared with its previous close of $1,423.80. In the last trading session, the stock traded between $1,419.77 and $1,449.64. It showed an upward intraday trend.

Return calculator

Time Period

An investment of $100 made 5 years ago in Eli Lilly is now worth

$ 556.02

Giving a profit of

$ 456.02 (456.02%)

Invest with $1

Note: Past profits do not guarantee future returns.

Analyst Overview

Buy

Rating from 24 Analysts

Buy
91.67%
Hold
4.17%
Sell
4.17%

Markets Today

Today's Change

+$19.92 (+1.40%)

Day High

$1,449.64

Day Low

$1,419.77

Day Open

$1,429.91

Prev Close

$1,423.80

Volume

14,90,448

1W Return

5.65%

1M Return

22.08%

3M Return

18.28%

6M Return

45.85%

1Y Return

41.85%

Fundamentals

Market Cap ($ Mn)

13,58,168

PE Ratio

46.85

PB Ratio

31.94

PEG Ratio

1.29

ROE

104.62%

ROCE

39.76%

EPS (TTM)

$7.24

Investment Returns

1 Week

5.65%

1 Month

22.08%

3 Months

18.28%

6 Months

45.85%

9 Months

39.05%

Financials

Quarterly
All values in $ Mn
15.6K

Jun 25
17.6K

Sep 25
19.3K

Dec 25
19.8K

Mar 26
23.0K

Jun 26
24.4K

Sep 26

Updates

14Nov

Eli Lilly presents obesity portfolio data at ObesityWeek 2026

Eli Lilly presented data across Zepbound, Foundayo, EloraTZP, and retatrutide at ObesityWeek 2026 (November 14-17, 2026, Washington, D.C.). EloraTZP Phase 2 results showed weight loss of up to an average of 54.1 lbs (23.3%) at 48 weeks from an average baseline of 232.4 lbs in adults with obesity or overweight and type 2 diabetes. Retatrutide reduced AHI by up to an average of 36.1 events per hour (60.6%) at 80 weeks in TRIUMPH-1, and by up to an average of 28.4 events per hour (48.1%) in TRIUMPH-2. Zepbound reduced BMI by an average of 21.4% in adolescents aged 12 to less than 18 years with obesity at 72 weeks in SURMOUNT-ADOLESCENTS. In the FOUNDERS survey, 96-98% of Foundayo users agreed the pill was simple, convenient, and easy to use.

Today
13Nov

Eli Lilly breaks ground on $3.5bn Pennsylvania obesity drug plant

Eli Lilly broke ground on a $3.5 billion manufacturing facility in Pennsylvania's Lehigh Valley. The site will produce injectable medicines, including the investigational obesity drug retatrutide. The project is expected to create 850 high-wage jobs and approximately 2,000 construction jobs. This investment is part of a broader $50 billion push to expand U.S. medicine production since 2020.

2 days ago
11Nov

Lilly Taltz-Zepbound combo shows durable efficacy in psoriatic arthritis

Taltz-Zepbound combo achieved 43.7% ACR50 response vs 15.7% for Taltz alone at Week 52. Composite endpoint (ACR50 + ≥10% weight loss) hit 39.2% in combo arm vs 1.7% in monotherapy. 85.7% of combination patients achieved ≥10% weight reduction compared to 6.7% on Taltz alone. Minimal Disease Activity reached 28.2% in combo arm versus 13.6% for monotherapy at Week 52.

3 days ago
11Nov

Eli Lilly, Gilead face near-term drug pricing risks as Washington intensifies scrutiny

Eli Lilly and Gilead face immediate exposure to Medicare price negotiations and Trump's most-favored-nation policy. Fifteen drugs account for $27 billion in Medicare spending, with new prices effective in 2028. Gilead's Biktarvy represents approximately 8% of its 2027 revenue, creating concentration risk. Most other pharma firms have only 0% to 3% of sales exposed to Medicare negotiations. Merck and Bristol Myers face larger pricing tests in 2029 when Keytruda and Opdivo become eligible.

3 days ago
9Nov

Lilly's Foundayo cuts sleep apnea severity by 44% in Phase 3 trial

Foundayo reduced apnea-hypopnea index by 43.8% in non-PAP users. Sleep apnea-specific hypoxic burden fell by up to 55.9%. Results presented at AHA Scientific Sessions 2026 and published in JAMA. FDA submission planned for end of 2026 for moderate-to-severe OSA treatment.

5 days ago
6Nov

Lilly, Hims & Hers expand access to FDA-approved obesity drugs

Eli Lilly and Hims & Hers partner to distribute FDA-approved obesity drugs via telehealth. Foundayo (oral) costs $149 per month; Zepbound (injectable) costs $299 per month. Patients receive prescriptions from licensed providers on the Hims & Hers platform. Agreement prohibits offering compounded copies of Lilly's GLP-1 medications.

9 days ago

Similar Stocks

StockLTPChange %Market CapPE
$285.89+0.83%$6,82,520.53M43.36
$295.06+0.21%$5,20,474.53M50.69
$147.72+0.52%$3,62,267.90M149.25
$160.51+0.16%$3,26,079.91M30.63
$184.50+0.06%$2,85,985.36M26.09
$465.65-0.30%$2,52,637.89M27.00
$168.04+0.05%$2,08,314.94M-
$28.90+0.23%$1,64,326.79M41.27
$41.64+2.43%$1,37,808.70M10.50
$63.42+1.77%$1,27,387.44M14.06
$48.36-0.21%$1,17,057.36M24.06
$50.47+1.44%$1,01,516.65M17.60